LGC

LGC will supply DNA fragmentation instruments for clinical and agricultural biotechnology customers.

The company will integrate the oligonucleotide manufacturer with two of its existing sections to form a new Nucleic Acid Chemistry business unit.

Backed by €15 million in EU funding, the Ubiquitous Pharmacogenomics Consortium seeks to implement preemptive testing at seven healthcare systems by 2020.

The partners will evaluate several quality control assays for genome editing research, eventually creating a protocol for analyzing mutations in genomic DNA.

The UK-based firm plans to marry its core strengths with the probes and PCR platforms, and to build its sales force in the US. 

LGC said it plans to use Douglas Scientific's PCR and qPCR platforms to provide customers with enhanced high-throughput genotyping and qPCR instruments.

The two companies will use KeyGene's technology for the genetic analysis of field and vegetable crops.

KKR Agrees to Buy LGC

The investment firm says it will acquire LGC for an undisclosed amount.

LGC will offer TraitGenetics' SNP genotyping services using Illumina and Affymetrix array technologies to its global customers.

The three-year deal includes more than 100,000 pre-designed assays for public domain human SNPs.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.